Kavanaugh, A., Coates, L., Mease, P., Nowak, M., Hippeli, L., Lehman, T., . . . Merola, J. (2024). Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial. Oxford University Press.
Citazione stile Chigago Style (17a edizione)Kavanaugh, A., LC Coates, PJ Mease, M. Nowak, L. Hippeli, T. Lehman, S. Banerjee, e JF Merola. Deucravacitinib, a Selective, TYK2 Inhibitor, in Psoriatic Arthritis: Achievement of Minimal Disease Activity Components in a Phase 2 Trial. Oxford University Press, 2024.
Citatione MLA (9a ed.)Kavanaugh, A., et al. Deucravacitinib, a Selective, TYK2 Inhibitor, in Psoriatic Arthritis: Achievement of Minimal Disease Activity Components in a Phase 2 Trial. Oxford University Press, 2024.